Global Myelodysplastic Syndrome (MDS) Drugs Market Size, Status and Forecast 2020-2026

Myelodysplastic syndrome is caused by mutation of one or more genes that control development of blood cells. It is one of the most common malignant hematological diseases that affects five out of every 100,000 people in U.S. annually. An estimated 60,000 people in U.S. live with MDS, and approximately 10,000-15,000 new cases are reported each year. Patients may present with clinical manifestations such as thrombocytopenia, neutropenia, and anemia. Exposure to chemicals (such as pesticides, tobacco, and benzene) and heavy metals (such as mercury and lead) may trigger disease onset.
In recent years, demand for hypomethylating agents has been at a high due to approval and adoption of Vidaza and Dacogen. A strong pipeline including Aranesp is expected to boost market growth in the near future. Easy availability of and access to novel treatments in major countries provides strong commercial opportunities to the market.
Market Analysis and Insights: Global Myelodysplastic Syndrome (MDS) Drugs Market
In 2019, the global Myelodysplastic Syndrome (MDS) Drugs market size was US$ 1411.9 million and it is expected to reach US$ 2094.1 million by the end of 2026, with a CAGR of 5.7% during 2021-2026.
Global Myelodysplastic Syndrome (MDS) Drugs Scope and Market Size
Myelodysplastic Syndrome (MDS) Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Myelodysplastic Syndrome (MDS) Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
Segment by Type, the Myelodysplastic Syndrome (MDS) Drugs market is segmented into Hypomethylating Agents, Immunomodulatory Drugs, Anti-anemics, etc.
Segment by Application, the Myelodysplastic Syndrome (MDS) Drugs market is segmented into Original, Generics, etc.
Regional and Country-level Analysis
The Myelodysplastic Syndrome (MDS) Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the Myelodysplastic Syndrome (MDS) Drugs market report are North America, Europe, China, Japan, Southeast Asia, India and Central & South America, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of revenue for the period 2015-2026.

Competitive Landscape

and Myelodysplastic Syndrome (MDS) Drugs Market Share Analysis
Myelodysplastic Syndrome (MDS) Drugs market competitive landscape provides details and data information by vendors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by player for the period 2015-2020. Details included are company description, major business, company total revenue and the revenue generated in Myelodysplastic Syndrome (MDS) Drugs business, the date to enter into the Myelodysplastic Syndrome (MDS) Drugs market, Myelodysplastic Syndrome (MDS) Drugs product introduction, recent developments, etc.
The major vendors include Celgene, Amgen, Otsuka, Takeda, etc.

This report focuses on the global Myelodysplastic Syndrome (MDS) Drugs status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Myelodysplastic Syndrome (MDS) Drugs development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

The key players covered in this study

Celgene
Amgen
Otsuka
Takeda
...

Market segment by Type, the product can be split into

Hypomethylating Agents
Immunomodulatory Drugs
Anti-anemics

Market segment by Application, split into

Original
Generics

Market segment by Regions/Countries, this report covers

North America
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:

To analyze global Myelodysplastic Syndrome (MDS) Drugs status, future forecast, growth opportunity, key market and key players.
To present the Myelodysplastic Syndrome (MDS) Drugs development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Myelodysplastic Syndrome (MDS) Drugs are as follows:
History Year: 2015-2019

Base Year:

2019

Estimated Year:

2020
Forecast Year 2020 to 2026
For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Frequently Asked Questions